Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody

BACKGROUND: Multiple anti-PD-L1/PD-1 checkpoint monoclonal antibodies (MAb) have shown clear evidence of clinical benefit. All except one have been designed or engineered to omit the possibility to mediate antibody-dependent cell-mediated cytotoxicity (ADCC) as a second potential mode of anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Donahue, Renee N., Lepone, Lauren M., Grenga, Italia, Jochems, Caroline, Fantini, Massimo, Madan, Ravi A., Heery, Christopher R., Gulley, James L., Schlom, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320726/
https://www.ncbi.nlm.nih.gov/pubmed/28239472
http://dx.doi.org/10.1186/s40425-017-0220-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5320726/
https://www.ncbi.nlm.nih.gov/pubmed/28239472
http://dx.doi.org/10.1186/s40425-017-0220-y

Ejemplares similares